Skip To Main Content
Jacob Sonenshine on Muck Rack

Jacob Sonenshine

Verified
New York
As seen in: Barron's, MSN, MSN Ireland, MSN Money Canada, Business Insider, Business Insider Nordic, USA Today, Yahoo News, Yahoo News New Zealand, Yahoo Singapore, Aol and
Reporter for @Barronsonline formerly @TheStreet, Formerly @MktsInsider Schooled @Hunter_College, Huge @Yankees fan Email: jacob.sonenshine@barrons.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jacob

Contact Jacob, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pharma stocks have rallied. 2 stocks to avoid—and 2 to buy.

|
By Jacob Sonenshine Verified
| MSN Verified
Biopharmaceutical stocks have emerged winners. Only some will continue to gain. The iShares Biotechnology Exchange-Traded Fund, home to some large pharma companies and many smaller biotechs, have risen over 6% this week. The main catalyst was that Moderna and Merck announced successful trial data for a melanoma vaccine that reduces the risk patients will experience recurrence. That sent the stocks of both companies soaring. It also sent the stock of most other drug makers up.
Open in Who Shared Issue with article?

Pharma Stocks Have Rallied. 2 Stocks to Avoid—and 2 to Buy.

|
By Jacob Sonenshine Verified
| Yahoo Finance Verified
The home to some large pharma companies and many smaller biotechs, have risen over 6% this week. The main catalyst was that Moderna and Merck announced successful trial data for a melanoma vaccine that reduces the risk patients will experience recurrence. “The read-through [from Merck and Moderna] to the others is probably indicative of a broader tailwind of pharma taking some strong actions to improve their long-term growth profiles,” says Cantor Fitzgerald analyst Carter Gould.
Open in Who Shared Issue with article?

7 Growth Stocks Holding Up in a Tough Market — Barrons.com

|
By Jacob Sonenshine Verified
| Trading View
7 Growth Stocks Holding Up in a Tough Market — Barrons.com LLY ZBRA Investors have been quick to punish stocks for signs of weakness in their businesses. Wolfe Research has identified seven companies that have managed to buck the trend. The stock market has become an unforgiving place. Chip stocks have been hit hard this summer amid concerns about how long the boom in artificial-intelligence infrastructure spending can last. A sharp rise in interest rates earlier this week added to the pressure.
Open in Who Shared Issue with article?
See all 5,982 licensed articles (5,983 Total)